Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.68 | -2.78 | -0.38 | 0.06 |
| FCF Yield | 4.77% | 3.91% | 5.73% | 9.78% |
| EV / EBITDA | 14.49 | 19.96 | 14.61 | 6.88 |
| Quality | ||||
| ROIC | 10.89% | 13.81% | 18.44% | 34.86% |
| Gross Margin | 86.13% | 82.89% | 85.99% | 83.05% |
| Cash Conversion Ratio | 1.00 | 1.16 | 1.16 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.27% | -6.55% | 12.73% | 34.83% |
| Free Cash Flow Growth | -0.08% | -17.11% | -32.23% | 225.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | -0.01 | -0.08 | -0.02 |
| Interest Coverage | 72.30 | 59.57 | 90.67 | 156.14 |
| Efficiency | ||||
| Inventory Turnover | 0.64 | 0.87 | 0.71 | 1.40 |
| Cash Conversion Cycle | 585.28 | 478.69 | 547.79 | 323.00 |